Failed Skin Cancer Tests Prompts Maxim Stock Drop
Biotech: Shareholders File Class Action Suit


Shares of San Diego-based Maxim Pharmaceuticals lost nearly half its value in trading after the biotechnology company announced its skin cancer drug Ceplene failed a pivotal trial...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99